Portal-Venous Hypothermic Oxygenated Perfusion in Liver Transplantation: Evidence Synthesis from the Bridge to HOPE Trial and Global Clinical Landscape

MedXY Editorial Team•Jun 4, 2026•Clinical Updates

The Bridge to HOPE trial (NCT05045794) established the superiority of end-ischemic portal-venous HOPE over static cold storage (SCS), reducing early allograft dysfunction (EAD) from 37.3% to 20.2%.
HOPE treatment leads to shorter hospital lengths of stay and improved metabolic function scores (MEAF) in recipients of extended criteria donor (ECD) grafts.
Beyond early function, HOPE improves biliary lipid secretion and reduces bile acid toxicity, potentially mitigating long-term nonanastomotic biliary strictures (NAS).
Emerging evidence suggests that HOPE possesses immunomodulatory properties, increasing donor-specific regulatory T cells and potentially reducing hepatocellular carcinoma (HCC) recurrence.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

The Bridge to HOPE trial (NCT05045794) established the superiority of end-ischemic portal-venous HOPE over static cold storage (SCS), reducing early allograft dysfunction (EAD) from 37.3% to 20.2%.
HOPE treatment leads to shorter hospital lengths of stay and improved metabolic function scores (MEAF) in recipients of extended criteria donor (ECD) grafts.
Beyond early function, HOPE improves biliary lipid secretion and reduces bile acid toxicity, potentially mitigating long-term nonanastomotic biliary strictures (NAS).
Emerging evidence suggests that HOPE possesses immunomodulatory properties, increasing donor-specific regulatory T cells and potentially reducing hepatocellular carcinoma (HCC) recurrence.